Pharmac's cardiovascular team prioritizes funding Wegovy for certain patients
Audio narration · Coming soon
Pharmac's cardiovascular experts have recommended prioritizing funding for the weight loss drug Wegovy. This recommendation targets individuals with cardiovascular disease and a BMI of 27 or higher, highlighting the drug's potential benefit for this specific group.
Why this matters
PRISM scored this story 55/100 for interest.
Originally published by gnews